What do docking and QSAR tell us about the design of HIV-1 reverse transcriptase nonnucleoside inhibitors?

about

What do docking and QSAR tell us about the design of HIV-1 reverse transcriptase nonnucleoside inhibitors?

Item

http://www.wikidata.org/entity/Q47136053

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

What do docking and QSAR tell ...... tase nonnucleoside inhibitors?

@en

What do docking and QSAR tell ...... tase nonnucleoside inhibitors?

@nl

type

Item

label

What do docking and QSAR tell ...... tase nonnucleoside inhibitors?

@en

What do docking and QSAR tell ...... tase nonnucleoside inhibitors?

@nl

prefLabel

What do docking and QSAR tell ...... tase nonnucleoside inhibitors?

@en

What do docking and QSAR tell ...... tase nonnucleoside inhibitors?

@nl

P1476

What do docking and QSAR tell ...... tase nonnucleoside inhibitors?

@en

P2093

Agata Paneth

http://www.w3.org/2001/XMLSchema#string

Wojciech Płonka

http://www.w3.org/2001/XMLSchema#string

P2860

The Protein Data Bank

Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.

Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design

Extremely High Mutation Rate of HIV-1 In Vivo

Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor

Detailed analysis of scoring functions for virtual screening.

Human immunodeficiency virus reverse transcriptase displays dramatically higher fidelity under physiological magnesium conditions in vitro.

Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations.

HIV-1 antiretroviral drug therapy.

In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).

P2888

s00894-017-3489-3

P304

317

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00894-017-3489-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Piotr Paneth

P577

2017-10-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29046967

http://www.w3.org/2001/XMLSchema#string

P932

5655543

http://www.w3.org/2001/XMLSchema#string